In an abstract presented at the ASH 2024 meeting, it was also shown to increase fibrinolytic activity, as demonstrated by elevated levels of tissue plasminogen activator (tPA) and prostacyclin (PGI2), in patients with acute chest syndrome related to sickle cell disease, highlighting its ability to reduce hypercoagulability [30]. Here, PLAT is linked to sickle cell disease.